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patients (mean age 65 years, mean Deyo-Charlson Comorbidity Index 0.6, mean
hospital length of stay 6.35 days); 214 cases and 214 controls were randomly se-
lected from the cohort for chart data analysis. In the 12 months post-index arthro-
plasty, there were 830 (2.5%) patients who had SSI, 644 (1.9%) who had SSB, and 84
(0.3%) who developed VTE. Of all SSI events, 65% occurred by 90 days following
arthroplasty. Significantly more patients who had received post-discharge throm-
boprophylaxis versus those that did not developed SSI but not SSB (SSI: 28.4% vs
23.2% [P0.0001]; SSB:28.5% vs 23.3% [P0.07]). In the logistic regression analysis,
only the duration of surgery (P0.004), surgical revision (P0.04), and rehospital-
ization (P0.001) emerged as independent predictors of SSI. CONCLUSIONS: Post-
discharge thromboprophylaxis and SSB were not associated with post-operative
SSI, thus dispelling concerns about the increased risk of developing SSI due to
prolonged SSB associated with the use of pharmacologic thromboprophylaxis. Ad-
ditional studies are needed to endorse these findings in similar patient popula-
tions.
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OBJECTIVES: The risk of post-discharge venous thromboembolism (VTE) and
bleeding in total knee and hip arthroplasty (TKA/THA) has not been completely
elucidated because interventions to reduce these adverse outcomes have evolved
rapidly. The objective of this study was to determine the incidence of these events
and associated risk factors, and to evaluate the use of thromboprophylaxis.
METHODS: Administrative medical records (2004–2009) from a large healthcare
plan were linked to an inpatient database of 450 hospitals in the United States.
Adult patients undergoing TKA or THA with no evidence of prior orthopaedic sur-
geries, prior VTE, post-discharge revision surgeries, or death were included. ICD-
9-CM diagnosis and CPT/HCPC procedure codes were used for evaluating symp-
tomatic VTE and bleeding rates 90 days post-surgery. Multivariate analyses were
performed to identify predictors of VTE and bleeding after hospitalization.
RESULTS: Two hundred twenty-six of 9167 patients (2.5%; 3109 THA, 6058 TKA)
with amedian age of 60 years and amean Charlson-Quan comorbidity index score
of 0.5 experienced VTE, and 324 (3.5%) had bleeding. Most of these events occurred
post-discharge (70% and 79%, respectively). Over 50% of VTE occurred within 30
days post-discharge. Consistent predictors of VTE and bleeding after hospitaliza-
tion were inpatient VTE or bleeding, respectively, and all-cause rehospitalization.
Post-discharge thromboprophylaxis was not a significant risk factor for bleeding.
Ninety-eight percent of patients received thromboprophylaxis during hospitaliza-
tion; 26% received it post-discharge. During hospitalization, three-fourths of pa-
tients received enoxaparin and/or warfarin, often in combination withmechanical
prophylaxis devices (57%). Post-discharge, mean antithrombotic drug exposure
was 7.4 days. CONCLUSIONS: Patients who experience VTE or bleeding during
hospitalization and patients who are rehospitalized are at greatest risk of throm-
boembolic and bleeding outcomes, respectively, post-discharge. These data also
suggest that the use of thromboprophylaxis following hospitalization should not
significantly increase the risk of post-discharge bleeding after TKA/THA.
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OBJECTIVES: Recent evidence has suggested that intra-arterial thrombolysis (IAT)
may provide benefit beyond intravenous thrombolysis (IVT) in ischemic stroke
patients. Previous meta-analyses have only compared IAT to standard treatment
[without thrombolysis]. The objective was to review the benefits and harms of IAT
in ischemic stroke patients. METHODS: EMBASE, MEDLINE, the Cochrane registry
and the stroke trials registry were queried from inception to 2011. Two reviewers
independently screened titles and abstracts for randomized controlled trials of
ischemic stroke comparing IAT to either IVT or standard treatment. Primary out-
comes included good functional outcome, excellent functional outcome, mortality
and symptomatic intracranial hemorrhage. Results were stratified by comparison
treatment. RESULTS: A total of 543 citations were identified. Two trials (n81)
compared IAT to IVT while the remaining four trials (n351) compared IAT to
standard treatment. IAT increased good functional outcome by 47% when com-
pared to standard treatment (RR1.47; 95%CI1.07-2.22; I20) and 74%when com-
pared to IVT (RR1.74; 95%CI1.01-3.01; I20). Excellent functional outcome was
73% higher with IATwhen compared to standard treatment (RR1.73; 95%CI1.17-
2.57; I20) and not significantly different when compared to IVT (RR1.74;
95%CI0.85-3.56), though only one trial reported results for the latter. IAT did not
increase mortality when compared to standard treatment (RR0.82; 95%CI0.56–
1.21; I20) or IVT (RR1.12; 95%CI0.47–2.68; I20). Syptomatic intracranial hem-
orrhage, however, was almost 4 times higher with IATwhen compared to standard
treatment (RR3.90; 95%CI1.41–10.76; I20)while not significantly differentwhen
compared to IVT (RR1.13; 95%CI0.32–3.99; I242%). CONCLUSIONS: Compared
to standard treatment, IAT increases good and excellent functional outcomes;
compared to IVT, IAT increases good functional outcome. As well, IAT does not
increase mortality over IVT or standard treatment. However, IAT increases symp-
tomatic intracranial hemorrhage compared to standard treatment while the risk
remains comparable to IVT. Imprecise pooled estimates for good and excellent
functional outcome prevent any overtly strong recommendation for the use of IAT.
PCV6
RISK OF ADVERSE CARDIOVASCULAR OUTCOMES ASSOCIATED WITH
CONCOMITANT USE OF CLOPIDOGREL AND PROTON PUMP INHIBITORS IN
ELDERLY MEDICARE BENEFICIARIES
Mahabaleshwarkar R, Yang Y, Datar M, Bentley JP, Strum M, Banahan BFI, Null KD
University of Mississippi, University, MS, USA
OBJECTIVES: Evidence regarding the effect of concomitant use of clopidogrel and
proton pump inhibitors (PPIs) on adverse cardiovascular outcomes remains incon-
clusive. The purpose of the current studywas to examine the effect of concomitant
use of clopidogrel and PPI in a national sample of elderly Medicare beneficiaries
(age 65 years).METHODS: The study used a nested case-control design. A cohort
of Medicare beneficiaries taking clopidogrel for any period between July 1, 2006 and
December 31, 2008 was identified from a 5% national sample of Medicare claims
data using prescription records. Beneficiaries who had a gap of more than 30 days
between clopidogrel fills were excluded. Within the continuous clopidogrel user
cohort, cases [beneficiaries who experienced amajor adverse cardiovascular event
(MACE, composite of acute myocardial infarction, coronary artery bypass graft,
percutaneous coronary intervention, stroke, and mortality)] and controls (benefi-
ciaries who did not experience a MACE) were identified from inpatient and outpa-
tient claims. Concomitant use of clopidogrel and PPI was ascertained using pre-
scription drug records. Each case wasmatched to a control on age and time to start
clopilogrel using a greedy match algorithm. Conditional logistic regression was
conducted on the matched sample to evaluate the association between concomi-
tant use and occurrence of a MACE. RESULTS: A cohort of 43,159 clopidogrel users
was identified. 15,722 of them (36.4%) used clopidogrel and PPI concomitantly at
any time during the study period. 9,332 cases were identified andmatched to equal
number of controls. Beneficiaries using clopidogrel and PPI concomitantly were
more likely to experience a MACE as compared to beneficiaries receiving clopi-
dogrel only (odds ratio: 1.411, 95% Confidence Interval: 1.322 – 1.506).
CONCLUSIONS: Concomitant use of clopidogrel and PPI was associated with an
increased risk of experiencing a cardiovascular adverse event. Caution should be
exercised when co-prescribing the two medications to elderly patients.
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OBJECTIVES: To quantify the impact of atrial fibrillation (AF) and major AF comor-
bidities on risk of cardiovascular (CV) hospitalization (CVH). METHODS: This ret-
rospective cohort study assessed an administrative claims database (Thomson
Reuters’ MarketScan) for newly diagnosed AF patients and demographically
matched non-AF patients to characterize risk of comorbidities and CVH among AF
patients. Patients aged40 yearswith364 days in the databasewere identified by
a qualifying AF diagnosis (2 outpatient diagnoses within 30 days of each other or
1 inpatient diagnosis) from January 1, 2004 to June 29, 2009. RESULTS: A total of
210,524 patients were included (mean age 74.012.5 years, 49% male, 68% Medi-
care). Compared with non-AF patients, AF patients were more likely prescribed
beta blockers (44% vs. 22%), digoxin (15% vs. 2%), and anticoagulants (29% vs. 2%);
had a higher severity of illness (Charlson Comorbidity Index score 4; 16.5% vs.
4.1%); and had higher comorbidity prevalence (odds ratio; 95% confidence interval):
myocardial infarction (13.1; 11.7-14.7), heart failure (HF; 9.2; 8.9-9.6), and pulmo-
nary embolism (8.2; 7.2-9.5). Risk of new CV events and comorbidities at follow-up
was significantly (P0.0001) higher inAFpatients,most notablymajor bleeding, HF,
valvular disease, and stroke. AF patients with baseline comorbidities related to
CHADS2 (score2) or CHA2DS2-VASc (score4) experienced2.5-fold higher rates
of overall CVH. AF patients had 3.4-fold higher CVH risk with30% hospitalized at
1 year vs. 8% of non-AF patients; 24.3% of AF patients experienced recurrent AF
requiring hospitalization (incidence: 176/1000 person-years). CONCLUSIONS: AF
patients have higher burden of baseline CV comorbidities that portend greater risk
of CVH and new CV comorbidities following diagnosis compared to matched
non-AF patients. These data indicate AF recurrence requiring hospitalization and
overall hospitalizations 1 year following diagnosis is common.
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OBJECTIVES: Time in therapeutic range (TTR) may be a quality indicator for anti-
coagulation. Previous studies have demonstrated that heart failure (HF) and other
comorbidities are associated with poorer anticoagulation control; however, this
associationwas not studied in a representative US population. The objectivewas to
determine the association between HF, other comorbidities, patient characteris-
tics, and TTR among patients with nonvalvular atrial fibrillation (NVAF).
METHODS: We analyzed longitudinal patient-level anticoagulation management
records collected between 2006 and 2010 by decision support software, Coag-
Clinic™. Adult patients with NVAF who used warfarin over 12 months with no gap
60 days between visits were identified. The Rosendaal method was used to cal-
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